MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585118 | Name: S 16020-2

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S 16020-2 is an olivacine derivative, and DNA topoisomerase II inhibitor endowed with a remarkable antitumor activity against various experimental tumors.

Chemical Structure

S 16020-2
S 16020-2
CAS#178169-99-8

Theoretical Analysis

MedKoo Cat#: 585118

Name: S 16020-2

CAS#: 178169-99-8

Chemical Formula: C22H26Cl2N4O2

Exact Mass: 448.1433

Molecular Weight: 449.38

Elemental Analysis: C, 58.80; H, 5.83; Cl, 15.78; N, 12.47; O, 7.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
S 16020-2; S16020-2; S-16020-2
IUPAC/Chemical Name
6H-Pyrido(4,3-b)carbazole-1-carboxamide, N-(2-(dimethylamino)ethyl)-9-hydroxy-5,6-dimethyl-, dihydrochloride
InChi Key
DSJBVXJNKBKZSB-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H24N4O2.2ClH/c1-13-15-7-8-23-20(22(28)24-9-10-25(2)3)17(15)12-18-16-11-14(27)5-6-19(16)26(4)21(13)18;;/h5-8,11-12,27H,9-10H2,1-4H3,(H,24,28);2*1H
SMILES Code
O=C(C1=NC=CC2=C(C)C(N(C)C3=C4C=C(O)C=C3)=C4C=C21)NCCN(C)C.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 449.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Guillonneau C, Nault A, Raimbaud E, Léonce S, Kraus-Berthier L, Pierré A, Goldstein S. Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues. Bioorg Med Chem. 2005 Jan 3;13(1):175-84. PubMed PMID: 15582462. 2: Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, Maurel P. The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-c arboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos. 2004 Jan;32(1):80-8. PubMed PMID: 14709624. 3: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PubMed PMID: 12808477. 4: Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. Epub 2002 Jun 25. PubMed PMID: 12172972. 5: Le Mée S, Chaminade F, Delaporte C, Markovits J, Saucier JM, Jacquemin-Sablon A. Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain. Mol Pharmacol. 2000 Oct;58(4):709-18. PubMed PMID: 10999940. 6: Malonne H, Farinelle S, Decaestecker C, Gordower L, Fontaine J, Chaminade F, Saucier JM, Atassi G, Kiss R. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. Clin Cancer Res. 2000 Sep;6(9):3774-82. PubMed PMID: 10999772. 7: Soudon J, Milano G, Poullain MG, Fischel JL, Formento P, Berlion M, Giroux B. Time-schedule dependency of S 16020, a new topoisomerase II inhibitor. Anticancer Drugs. 1999 Jul;10(6):597-604. PubMed PMID: 10885908. 8: Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res. 2000 Jan;6(1):297-304. PubMed PMID: 10656461. 9: Guillonneau C, PierréA, Charton Y, Guilbaud N, Kraus-Berthier L, Léonce S, Michel A, Bisagni E, Atassi G. Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity. J Med Chem. 1999 Jun 17;42(12):2191-203. PubMed PMID: 10377224. 10: Pierré A, Léonce S, Pérez V, Atassi G. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother Pharmacol. 1998;42(6):454-60. PubMed PMID: 9788571. 11: Le Mée S, Pierré A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol. 1998 Feb;53(2):213-20. PubMed PMID: 9463478. 12: Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G. Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur J Cancer. 1997 Oct;33(11):1881-7. PubMed PMID: 9470851. 13: Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997 Oct;8(9):811-22. Review. PubMed PMID: 9402307. 14: Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierré A, Atassi G. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anticancer Drugs. 1997 Mar;8(3):276-82. PubMed PMID: 9095333. 15: Léonce S, Perez V, Casabianca-Pignede MR, Anstett M, Bisagni E, Pierré A, Atassi G. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs. 1996;14(2):169-80. PubMed PMID: 8913838. 16: Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol. 1996;38(6):513-21. PubMed PMID: 8823492.

View History

F 522

F 522

L 157012

L 157012

G-31406 HCl

G-31406 HCl